Baidu
map

药械指南

订阅

MedSci主页 / 所有栏目 / 药械指南

2022 意大利指南：多发病和多重用药患者的管理

2022-03-06 国外老年医学专家组（统称） Aging Clin Exp Res

多发病和多重用药

多发病和多重用药患者的管理既复杂有充满挑战，本文主要针对多发病和/或多重用药患者的管理提供指导建议，以提高其护理质量。主要建议内容涉及一般原则，个体化方法和目标人群，多发病和多重用药患者的个体化管理，

中文标题：

2022 意大利指南：多发病和多重用药患者的管理

英文标题：

Italian guidelines on management of persons with multimorbidity and polypharmacy

发布机构：

国外老年医学专家组（统称）

发布日期：

2022-03-06

简要介绍：

多发病和多重用药患者的管理既复杂有充满挑战，本文主要针对多发病和/或多重用药患者的管理提供指导建议，以提高其护理质量。主要建议内容涉及一般原则，个体化方法和目标人群，多发病和多重用药患者的个体化管理，护理模式。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2022 意大利指南：多发病和多重用药患者的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=f5a151c0023e57f5, title=2022 意大利指南：多发病和多重用药患者的管理, enTitle=Italian guidelines on management of persons with multimorbidity and polypharmacy, guiderFrom=Aging Clin Exp Res, authorId=0, author=, summary=多发病和多重用药患者的管理既复杂有充满挑战，本文主要针对多发病和/或多重用药患者的管理提供指导建议，以提高其护理质量。主要建议内容涉及一般原则，个体化方法和目标人群，多发病和多重用药患者的个体化管理，, cover=https://img.medsci.cn/202238/1646745490442_1608702.jpg, journalId=0, articlesId=null, associationId=2025, associationName=国外老年医学专家组（统称）, associationIntro=国外老年医学专家组（统称）, copyright=0, guiderPublishedTime=Sun Mar 06 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">多发病和多重用药患者的管理既复杂有充满挑战，本文主要针对多发病和/或多重用药患者的管理提供指导建议，以提高其护理质量。主要建议内容涉及一般原则，个体化方法和目标人群，多发病和多重用药患者的个体化管理，护理模式。</span></p>, tagList=[TagDto(tagId=124067, tagName=多发病和多重用药)], categoryList=[CategoryDto(categoryId=11, categoryName=药械, tenant=100), CategoryDto(categoryId=19, categoryName=老年医学, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=30090, articleKeyword=多重用药, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=9201, appHits=71, showAppHits=0, pcHits=410, showPcHits=9130, likes=1, shares=5, comments=4, approvalStatus=1, publishedTime=Wed Mar 09 15:16:00 CST 2022, publishedTimeString=2022-03-06, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=dajiong, createdTime=Tue Mar 08 21:19:10 CST 2022, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 20:06:49 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 意大利指南：多发病和多重用药患者的管理.pdf)])
2022 意大利指南：多发病和多重用药患者的管理.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2110217, encodeId=7ca0211021e98, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f022492982, createdName=12481688m22暂无昵称, createdTime=Sat Jan 14 18:47:47 CST 2023, time=2023-01-14, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1242349, encodeId=8095124234936, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404d8302519, createdName=ms3000001333551939, createdTime=Wed Aug 31 21:58:34 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212197, encodeId=f45e121219e90, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201117/5280595f4a8d4ca7ab73b174d9c3c0db/1046ed60076e4eb7af96ed8150a5d41d.jpg, createdBy=58fb5435671, createdName=夜空中的星星, createdTime=Mon Apr 18 15:30:29 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201126, encodeId=77b31201126ac, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3235550963, createdName=ms3000001460786340, createdTime=Thu Mar 10 07:21:47 CST 2022, time=2022-03-10, status=1, ipAttribution=)]
    2023-01-14 12481688m22暂无昵称 来自福建省

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2110217, encodeId=7ca0211021e98, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f022492982, createdName=12481688m22暂无昵称, createdTime=Sat Jan 14 18:47:47 CST 2023, time=2023-01-14, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1242349, encodeId=8095124234936, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404d8302519, createdName=ms3000001333551939, createdTime=Wed Aug 31 21:58:34 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212197, encodeId=f45e121219e90, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201117/5280595f4a8d4ca7ab73b174d9c3c0db/1046ed60076e4eb7af96ed8150a5d41d.jpg, createdBy=58fb5435671, createdName=夜空中的星星, createdTime=Mon Apr 18 15:30:29 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201126, encodeId=77b31201126ac, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3235550963, createdName=ms3000001460786340, createdTime=Thu Mar 10 07:21:47 CST 2022, time=2022-03-10, status=1, ipAttribution=)]
    2022-08-31 ms3000001333551939

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2110217, encodeId=7ca0211021e98, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f022492982, createdName=12481688m22暂无昵称, createdTime=Sat Jan 14 18:47:47 CST 2023, time=2023-01-14, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1242349, encodeId=8095124234936, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404d8302519, createdName=ms3000001333551939, createdTime=Wed Aug 31 21:58:34 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212197, encodeId=f45e121219e90, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201117/5280595f4a8d4ca7ab73b174d9c3c0db/1046ed60076e4eb7af96ed8150a5d41d.jpg, createdBy=58fb5435671, createdName=夜空中的星星, createdTime=Mon Apr 18 15:30:29 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201126, encodeId=77b31201126ac, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3235550963, createdName=ms3000001460786340, createdTime=Thu Mar 10 07:21:47 CST 2022, time=2022-03-10, status=1, ipAttribution=)]
    2022-04-18 夜空中的星星

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2110217, encodeId=7ca0211021e98, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f022492982, createdName=12481688m22暂无昵称, createdTime=Sat Jan 14 18:47:47 CST 2023, time=2023-01-14, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1242349, encodeId=8095124234936, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404d8302519, createdName=ms3000001333551939, createdTime=Wed Aug 31 21:58:34 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212197, encodeId=f45e121219e90, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201117/5280595f4a8d4ca7ab73b174d9c3c0db/1046ed60076e4eb7af96ed8150a5d41d.jpg, createdBy=58fb5435671, createdName=夜空中的星星, createdTime=Mon Apr 18 15:30:29 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201126, encodeId=77b31201126ac, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3235550963, createdName=ms3000001460786340, createdTime=Thu Mar 10 07:21:47 CST 2022, time=2022-03-10, status=1, ipAttribution=)]
    2022-03-10 ms3000001460786340

    学习

    0

拓展阅读

北京天坛医院开设MTM门诊，教患者如何“吃药”

患有多种疾病，看了几个科室、开了好几种药，这些药哪个先吃、哪个后吃，能不能一起吃？这些问题困扰着不少患者。10月24日，为了解决患者用药方面疑问，位于北京南四环花乡桥东北的天坛医院新院区推出“多重用药治疗管理（MTM）门诊”，由专业药师为患者答疑解惑。

JAMA：美国成人处方药的使用呈上升趋势

1

Baidu
map
Baidu
map
Baidu
map